Published in Cancer on September 01, 1976
Chemotherapy and human chorionic gonadotropin concentrations 6 months after uterine evacuation of molar pregnancy: a retrospective cohort study. Lancet (2011) 1.51
Problems of interpretation of serum concentrations of alpha-foetoprotein (AFP) in patients receiving cytotoxic chemotherapy for malignant germ cell tumours. Br J Cancer (1983) 1.40
Third Gordon Hamilton-Fairley Memorial Lecture. Tumour markers--where do we go from here? Br J Cancer (1983) 1.12
Pregnancy after cytotoxic chemotherapy for gestational trophoblastic tumours. Br Med J (Clin Res Ed) (1984) 1.07
The management and outcome of women with post-hydatidiform mole 'low-risk' gestational trophoblastic neoplasia, but hCG levels in excess of 100 000 IU l(-1). Br J Cancer (2010) 1.06
Current chemotherapeutic management of patients with gestational trophoblastic neoplasia. Chemother Res Pract (2011) 1.06
The significance of the time interval between antecedent pregnancy and diagnosis of high-risk gestational trophoblastic tumours. Br J Cancer (2006) 1.04
Gestational trophoblastic disease: a multimodality imaging approach with impact on diagnosis and management. Radiol Res Pract (2014) 0.98
Testicular germ cell tumours--a model for a new approach to treatment of adult solid tumours. Postgrad Med J (1985) 0.97
Pulmonary function in patients with trophoblastic disease treated with low-dose methotrexate. Br J Cancer (1997) 0.97
The presentation and management of post-partum choriocarcinoma. Br J Cancer (1999) 0.90
A comparison of patients with relapsed and chemo-refractory gestational trophoblastic neoplasia. Br J Cancer (2007) 0.90
Doppler assessment of the uterine circulation and the clinical behaviour of gestational trophoblastic tumours requiring chemotherapy. Br J Cancer (1992) 0.87
Uterine artery pulsatility index: a predictor of methotrexate resistance in gestational trophoblastic neoplasia. Br J Cancer (2012) 0.87
Lessons from choriocarcinoma. Proc R Soc Med (1977) 0.87
Competing risks determining event-free survival in early breast cancer. Br J Cancer (1992) 0.83
Treatment of persistent trophoblastic disease later than 6 months after diagnosis of molar pregnancy. Br J Cancer (2000) 0.83
Marker proteins as indicators of tumour response to therapy. Br J Cancer Suppl (1980) 0.81
Walker Prize Lecture, 1977. Choriocarcinoma: can we afford to cure cancer. Ann R Coll Surg Engl (1978) 0.81
CA 125 and survival in ovarian cancer: preliminary communication. J R Soc Med (1988) 0.78
The role of surgery and radiation therapy in the management of gestational trophoblastic disease. Oncologist (2010) 0.76
Residual lung lesions after completion of chemotherapy for gestational trophoblastic neoplasia: should we operate? Br J Cancer (2006) 0.76
Long-term effects of chemotherapy on lymphocyte chromosomes from patients treated for gestational trophoblastic tumours. Br J Cancer (1985) 0.75
Curable metastatic cancer in young women. Br Med J (Clin Res Ed) (1987) 0.75
Further studies on immunological parameters in gestational trophoblastic neoplasia. Arch Gynecol (1984) 0.75
Limits of therapy for malignant chorioepithelioma. Arch Gynecol (1979) 0.75
First annual meeting of the Association of Cancer Physicians (in conjunction with the 27th AGM of the British Association for Cancer Research). March 24-26, 1986, Bristol, UK. Abstracts. Br J Cancer (1986) 0.75
Massive fetomaternal hemorrhage caused by an intraplacental choriocarcinoma: a case report. Case Rep Med (2010) 0.75
Activity of high-dose cis-platinum (NCI 119875) in combination with vincristine and methotrexate in drug-resistant gestational choriocarcinoma. A report of 17 cases. Br J Cancer (1979) 0.75
Update in cancer chemotherapy: genitourinary tract cancer, Part 7: Gestational trophoblastic neoplasms. J Natl Med Assoc (1988) 0.75
Computer system for assisting with clinical interpretation of tumour marker data. BMJ (1992) 0.75
Tumour markers in malignancies. Two isoforms of oestrogen receptor are now known to exist. BMJ (2000) 0.75
First-line chemotherapy in low-risk gestational trophoblastic neoplasia. Cochrane Database Syst Rev (2012) 0.75
Radioimmunoassay for human chorionic gonadotrophin and luteinising hormone. Lancet (1966) 2.82
Tumour growth and anti-mitotic action. The role of spontaneous cell losses. Br J Cancer (1968) 2.34
Hydatidiform mole in England and Wales 1973-83. Lancet (1986) 2.05
EMA/CO for high-risk gestational trophoblastic tumors: results from a cohort of 272 patients. J Clin Oncol (1997) 2.00
Comparison of ondansetron and ondansetron plus dexamethasone as antiemetic prophylaxis during cisplatin-containing chemotherapy. Lancet (1991) 1.95
Further advances in the management of malignant teratomas of the testis and other sites. Lancet (1983) 1.80
Accurate quantification of 131I distribution by gamma camera imaging. Eur J Nucl Med (1990) 1.78
The masking of antigens on trophoblast and cancer cells. Lancet (1967) 1.65
Tumour specific immunogenicity of methylcholanthrene-induced sarcoma cells after incubation in neuraminidase. Br J Cancer (1969) 1.59
Effects of microwave cookery on the bacterial counts of food. J Appl Bacteriol (1965) 1.58
ABO blood-groups in trophoblastic neoplasia. Lancet (1971) 1.56
Immunohistological distribution of 5T4 antigen in normal and malignant tissues. Br J Cancer (1990) 1.56
Combination but not single-agent methotrexate chemotherapy for gestational trophoblastic tumors increases the incidence of second tumors. J Clin Oncol (1996) 1.54
Developments in chemotherapy for medium- and high-risk patients with gestational trophoblastic tumours (1979-1984). Br J Obstet Gynaecol (1986) 1.53
Tumour-marker levels and prognosis in malignant teratoma of the testis. Br J Cancer (1980) 1.49
Current optimum management of anaplastic germ cell tumours of the testis and other sites. Br J Urol (1986) 1.48
A rapid, sensitive and specific radioimmunoassay for human chorionic gonadotrophin. J Immunol Methods (1976) 1.47
Effect of neuraminidase on the immunogenicity of early mouse trophoblast. Nature (1968) 1.44
The role of sialic acid in antigenic expression: further studies of the Landschütz ascites tumour. Br J Cancer (1968) 1.42
Chemotherapy of advanced malignant teratomas. Br J Cancer (1980) 1.40
Problems of interpretation of serum concentrations of alpha-foetoprotein (AFP) in patients receiving cytotoxic chemotherapy for malignant germ cell tumours. Br J Cancer (1983) 1.40
Frequency of serum tumour marker monitoring in patients with non-seminomatous germ cell tumours. Br J Cancer (1990) 1.39
Distribution of the Ca (Oxford) antigen in lung neoplasms and non-neoplastic lung tissues. J Clin Pathol (1984) 1.35
Follow-up after hydatidiform mole: studies using radioimmunoassay for urinary human chorionic gonadotrophin (HCG). J Obstet Gynaecol Br Commonw (1973) 1.34
Choriocarcinoma after hydatidiform mole. Studies related to effectiveness of follow-up practice after hydatidiform mole. Br Med J (1969) 1.34
Immunogenicity of L 1210 murine leukaemia cells after treatment with neuraminidase. Nature (1968) 1.31
Central nervous system metastases of choriocarcinoma. 23 years' experience at Charing Cross Hospital. Cancer (1983) 1.31
Immunodiagnosis and monitoring of gonadotrophin-producing metastases in the central nervous system. Cancer (1976) 1.30
Radioimmunoassay methods for carcinoembryonic antigen. J Immunol Methods (1974) 1.27
Pelvic arteriography in invasive trophoblastic neoplasia. Br J Radiol (1968) 1.24
Serum-SP1-pregnancy-specific-beta-glycoprotein in choriocarcinoma and other neoplastic disease. Lancet (1978) 1.21
Use of CA-125 to predict survival of patients with ovarian carcinoma. North Thames Cooperative Group. J Clin Oncol (1989) 1.20
Medical presentations of choriocarcinoma. Br Med J (1971) 1.17
Computer controlled automated radioimmunoassay. Lab Pract (1975) 1.17
What sort of oncology team should treat testicular teratoma? Lancet (1985) 1.16
Liposomally entrapped second antibody improves tumour imaging with radiolabelled (first) antitumour antibody. Lancet (1982) 1.15
Acquisition of Staphylococcus aureus by patients undergoing cytotoxic therapy in an ultra-clean isolation unit. J Hyg (Lond) (1966) 1.14
Weekly alternating etoposide, methotrexate, and actinomycin/vincristine and cyclophosphamide chemotherapy for the treatment of CNS metastases of choriocarcinoma. J Clin Oncol (1989) 1.14
The HL-A system in trophoblastic neoplasia. Lancet (1971) 1.12
Antibody distribution and dosimetry in patients receiving radiolabelled antibody therapy for colorectal cancer. Br J Cancer (1989) 1.12
The effect of neuraminidase on the immunogenicity of the Landschütz ascites tumour: site and mode of action. Br J Cancer (1968) 1.12
Third Gordon Hamilton-Fairley Memorial Lecture. Tumour markers--where do we go from here? Br J Cancer (1983) 1.12
A human choriocarcinoma xenograft in nude mice; a model for the study of antibody localization. Br J Cancer (1981) 1.11
The cytotoxicity, DNA crosslinking ability and DNA sequence selectivity of the aniline mustards melphalan, chlorambucil and 4-[bis(2-chloroethyl)amino] benzoic acid. Biochem Pharmacol (1992) 1.10
Ondansetron (GR38032F) plus dexamethasone: effective anti-emetic prophylaxis for patients receiving cytotoxic chemotherapy. Br J Cancer (1990) 1.10
Recent observations related to the chemotherapy and immunology of gestational choriocarcinoma. Adv Cancer Res (1973) 1.09
Urinary gonadotrophin peptide--isolation and purification, and its immunohistochemical distribution in normal and neoplastic tissues. Br J Cancer (1988) 1.08
A sensitive radioimmunoassay for human chorionic gonadotrophin and luteinizing hormone. J Endocrinol (1967) 1.08
Pregnancy after cytotoxic chemotherapy for gestational trophoblastic tumours. Br Med J (Clin Res Ed) (1984) 1.07
Repeated antitumour antibody therapy in man with suppression of the host response by cyclosporin A. Br J Cancer (1988) 1.06
Epipodophylin derivative (VP 16-23) in malignant teratomas and choriocarcinomas. Lancet (1977) 1.06
Relationship of oral contraception to development of trophoblastic tumour after evacuation of a hydatidiform mole. Br J Obstet Gynaecol (1976) 1.05
Macrophage electrophoretic mobility (MEM) with myelin basic protein. Br J Cancer (1976) 1.05
Relationship between concentrations of human chorionic gonadotrophin in plasma and cerebrospinal fluid. Nature (1968) 1.05
Safety of surveillance in the management of stage I anaplastic germ cell tumours of the testis. Br J Urol (1988) 1.05
Cardio-respiratory aspects of trophoblastic tumours. Q J Med (1966) 1.04
Extraction and preliminary characterization of a human bronchogenic carcinoma antigen. Br J Cancer (1975) 1.04
Management of resistant gestational trophoblastic tumors. J Reprod Med (1998) 1.02
Dose-dependent localisation and potential for therapy of F(ab')2 fragments against CEA studied in a human tumour xenograft model. Br J Cancer (1986) 1.02
Results with the EMA/CO (etoposide, methotrexate, actinomycin D, cyclophosphamide, vincristine) regimen in high risk gestational trophoblastic tumours, 1979 to 1989. Br J Obstet Gynaecol (1991) 1.01
Long-term outcome in patients with germ cell tumours treated with POMB/ACE chemotherapy: comparison of commonly used classification systems of good and poor prognosis. Br J Cancer (1989) 1.01
Carcinoembryonic antigen: isolation of a sub-fraction with high specific activity. Br J Cancer (1976) 1.01
The effect of radiosensitizers on radio-immunotherapy, using 131I-labelled anti-CEA antibodies in a human colonic xenograft model. Int J Cancer (1991) 1.00
Radioimmunoassay and saturation analysis. Tumor-associated antigens. Br Med Bull (1974) 1.00
Response of differentiated but not anaplastic teratoma to interferon. Br J Cancer (1984) 1.00
Ablation of human choriocarcinoma xenografts in nude mice by antibody-directed enzyme prodrug therapy (ADEPT) with three novel compounds. Eur J Cancer (1991) 0.99
Placental site trophoblastic tumour (trophoblastic pseudotumour): a study of four cases requiring hysterectomy including one fatal case. Histopathology (1982) 0.99
Antibody-directed enzyme prodrug therapy: efficacy and mechanism of action in colorectal carcinoma. Clin Cancer Res (2000) 0.98
Inactivation and clearance of an anti-CEA carboxypeptidase G2 conjugate in blood after localisation in a xenograft model. Br J Cancer (1990) 0.97
Unmasking moles. Br J Obstet Gynaecol (1982) 0.97
Twenty years of anaplastic germ cell tumours. J R Soc Med (1984) 0.97
Cellular reaction in trophoblastic tumours. Br J Cancer (1973) 0.96
Comparative tumour localization of antibody fragments and intact IgG in nude mice bearing a CEA-producing human colon tumour xenograft. Eur J Cancer Clin Oncol (1985) 0.96
Isolating patients in hospital to control infection. Part I--Sources and routes of infection. Br Med J (1978) 0.96
Fatal hypoglycemia after cytotoxic chemotherapy: a report of two cases and a review of the literature. Cancer (1979) 0.96
Bone disease in testicular and extragonadal germ cell tumours. Br J Cancer (1988) 0.95
A clinical, histopathological and flow cytometric study of 149 complete moles, 146 partial moles and 107 non-molar hydropic abortions. Histopathology (1996) 0.95
Radioimmunolocalization of tumours by external scintigraphy after administration of 131I antibody to human chorionic gonadotrophin: preliminary communication. J R Soc Med (1980) 0.94
Human immune response to monoclonal antibody-enzyme conjugates in ADEPT pilot clinical trial. Cell Biophys (1994) 0.93
Gestational and nongestational trophoblastic tumors distinguished by DNA analysis. Cancer (1992) 0.93
Cancer drug targeting. Clin Radiol (1985) 0.93
Successful management of metastatic and primary germ cell tumors in the brain. Cancer (1986) 0.93
Gonadotrophin excretion, pelvic arteriography and treatment in post-molar trophoblastic disease. Proc R Soc Med (1967) 0.93
An analysis of the influences of maternal age, gestational age, contraceptive method, and the mode of primary treatment of patients with hydatidiform moles on the incidence of subsequent chemotherapy. Br J Obstet Gynaecol (1979) 0.93
Optimisation of small-scale coupling of A5B7 monoclonal antibody to carboxypeptidase G2. J Immunol Methods (1993) 0.93
Optimum management of pineal germ cell tumours. Clin Oncol (R Coll Radiol) (1991) 0.93
The effect of serum CEA on the distribution and clearance of anti-CEA antibody in a pancreatic tumour xenograft model. Br J Cancer (1989) 0.92
A phase-I study of repeated therapy with radiolabelled antibody to carcinoembryonic antigen using intermittent or continuous administration of cyclosporin A to suppress the immune response. Int J Cancer (1991) 0.92
Fertility after chemotherapy for male and female germ cell tumours. Int J Androl (1987) 0.92
Heterogeneity of carcinoembryonic antigen and its fractionation by con A affinity chromatography. Nature (1974) 0.91
Is ectopic production of human chorionic gonadotrophin (hCG) or alpha fetoprotein (AFP) by tumours a marker of chemosensitivity? Eur J Cancer Clin Oncol (1986) 0.91
Preliminary therapeutic and localization studies with human chorionic gonadotrophin. Cancer Res (1980) 0.91
Treatment of high-risk choriocarcinoma. J Reprod Med (1984) 0.91
Placental-type alkaline phosphatase from human tumour tissue. Clin Chim Acta (1971) 0.90
Novel prodrugs which are activated to cytotoxic alkylating agents by carboxypeptidase G2. J Med Chem (1990) 0.90
HL-A matings in trophoblastic neoplasia. Tissue Antigens (1972) 0.90
The concentration of HCG in the plasma and spinal fluid of patients with trophoblastic tumours in the central nervous system. Br J Cancer (1968) 0.90
Dynamics of monoclonal antibody distribution and prolonged tumour localisation in nude mice bearing a human CEA-producing colon carcinoma xenograft. Tumour Biol (1986) 0.90
Galactosylated antibodies and antibody-enzyme conjugates in antibody-directed enzyme prodrug therapy. Cancer (1994) 0.89